| Date Checked | 2025-12-21 23:39:18 |
|---|---|
| Graham Number | (PB)nan vs (PE)0.00 |
| Over / Under Value Percentage | 0.00% vs 0.00% |
| Dividend Yield | 0.00% |
| Dividend Date | 2019-06-07 |
| Symbol | JAGX |
| AssetType | Common Stock |
| Name | Jaguar Animal Health Inc |
| Description | Jaguar Animal Health, Inc. (JAGX) is a commercial-stage biopharmaceutical company based in San Francisco, specializing in innovative prescription therapies for human and animal health. With a strong focus on addressing chronic gastrointestinal disorders and debilitating diarrhea, the company leverages proprietary technologies derived from extensive microbiome research to develop effective and sustainable healthcare solutions. As the demand for effective gastrointestinal treatments grows, Jaguar Health’s advancements and commitment to enhancing quality of life position it strategically within the biopharmaceutical industry, making it a noteworthy entity for institutional investors seeking opportunities in this expanding market. |
| CIK | 1585608 |
| Exchange | NASDAQ |
| Currency | USD |
| Country | USA |
| Sector | HEALTHCARE |
| Industry | BIOTECHNOLOGY |
| Address | 200 PINE STREET, SAN FRANCISCO, CA, UNITED STATES, 94104 |
| OfficialSite | https://jaguar.health |
| FiscalYearEnd | December |
| LatestQuarter | 2025-09-30 |
| MarketCapitalization | 4885700 |
| EBITDA | -30909000 |
| PERatio | 0 |
| PEGRatio | -0.02 |
| BookValue | 0.852 |
| DividendPerShare | None |
| EPS | -2.58 |
| RevenuePerShareTTM | 10.16 |
| ProfitMargin | 0 |
| OperatingMarginTTM | -2.348 |
| ReturnOnAssetsTTM | -0.38 |
| ReturnOnEquityTTM | -4.116 |
| RevenueTTM | 11785000 |
| GrossProfitTTM | 9654000 |
| DilutedEPSTTM | -2.58 |
| QuarterlyEarningsGrowthYOY | 0 |
| QuarterlyRevenueGrowthYOY | -0.008 |
| AnalystTargetPrice | 25.5 |
| AnalystRatingStrongBuy | - |
| AnalystRatingBuy | - |
| AnalystRatingHold | - |
| AnalystRatingSell | - |
| AnalystRatingStrongSell | - |
| TrailingPE | - |
| ForwardPE | - |
| PriceToSalesRatioTTM | 0.415 |
| PriceToBookRatio | 1.542 |
| EVToRevenue | 3.029 |
| EVToEBITDA | -0.63 |
| Beta | -0.104 |
| 52WeekHigh | 33.25 |
| 52WeekLow | 1 |
| 50DayMovingAverage | 1.637 |
| 200DayMovingAverage | 3.717 |
| SharesOutstanding | 4175800 |
| SharesFloat | 2473900 |
| PercentInsiders | 30.954 |
| PercentInstitutions | 2.101 |
| ExDividendDate | None |
| dateChecked | 2025-12-21 23:39:18 |
| fresh | 1 |